Jean H Tayar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6710998/publications.pdf

Version: 2024-02-01

713013 840119 25 953 11 21 h-index citations g-index papers 25 25 25 1538 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Risk of Malignancies in Patients With Rheumatoid Arthritis Treated With Biologic Therapy. JAMA - Journal of the American Medical Association, 2012, 308, 898.	3.8	259
2	Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience., 2019, 7, 2.		213
3	Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series. Annals of the Rheumatic Diseases, 2017, 76, 2061-2064.	0.5	141
4	Myositis as an adverse event of immune checkpoint blockade for cancer therapy. Seminars in Arthritis and Rheumatism, 2019, 48, 736-740.	1.6	90
5	Severe Hyperosmolar Metabolic Acidosis Due to a Large Dose of Intravenous Lorazepam. New England Journal of Medicine, 2002, 346, 1253-1254.	13.9	39
6	Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nature Communications, 2022, 13, 1970.	5.8	34
7	Febuxostat for treating chronic gout. The Cochrane Library, 2012, 11, CD008653.	1.5	29
8	Genetic determinants of immune-related adverse events in patients with melanoma receiving immune checkpoint inhibitors. Cancer Immunology, Immunotherapy, 2021, 70, 1939-1949.	2.0	27
9	New understanding and approaches to treatment in rheumatoid arthritis. British Medical Bulletin, 2010, 94, 201-214.	2.7	22
10	Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients: A case series. Antiviral Research, 2016, 135, 91-96.	1.9	20
11	Systematic review of observational studies reporting antiphospholipid antibodies in patients with solid tumors. Blood Advances, 2020, 4, 1746-1755.	2.5	17
12	Outcome of acute limb ischemia in cancer patients. Vascular Medicine, 2014, 19, 112-117.	0.8	14
13	Case 181: Synovitis Acne Pustulosis Hyperostosis Osteitis (SAPHO) Syndrome. Radiology, 2012, 263, 613-617.	3.6	9
14	Overall survival in patients with rheumatoid arthritis and solid malignancies receiving biologic disease-modifying antirheumatic therapy. Clinical Rheumatology, 2020, 39, 2943-2950.	1.0	8
15	Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer. Clinical Rheumatology, 2020, 39, 787-794.	1.0	7
16	Case Discussion and Literature Review: Cancer Immunotherapy, Severe Immune-Related Adverse Events, Multi-Inflammatory Syndrome, and Severe Acute Respiratory Syndrome Coronavirus 2. Frontiers in Oncology, 2021, 11, 625707.	1.3	7
17	Primary autoimmune myelofibrosis as etiology of pancytopenia mimicking myelodysplastic syndrome. Leukemia and Lymphoma, 2016, 57, 731-734.	0.6	4
18	Coronary Lesions in Takayasu Arteritis With Chronic Myelogenous Leukemia ― Intravascular Assessment With Optical Coherence Tomography and Fractional Flow Reserve ―. Circulation Journal, 2018, 83, 245-246.	0.7	4

#	Article	IF	CITATIONS
19	Improvement of Smoking Abstinence Rates With Increased Varenicline Dosage. Journal of Clinical Psychopharmacology, 2018, 38, 34-41.	0.7	3
20	Adalimumab: 8 years of experience in rheumatoid arthritis. International Journal of Clinical Rheumatology, 2013, 8, 165-184.	0.3	2
21	Newly developed pseudogout arthritis after therapy with MAGE-A4 directed TCR T cells responded to treatment with tocilizumab., 2021, 9, e002716.		2
22	The updated guidelines on the use of rituximab in rheumatoid arthritis. Rheumatology, 2011, 50, 2153-2154.	0.9	1
23	Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma. Journal of Immunotherapy and Precision Oncology, 2022, 5, 26-30.	0.6	1
24	Case 181. Radiology, 2012, 262, 361-363.	3.6	0
25	Bupropion XL and SR have similar effectiveness and adverse event profiles when used to treat smoking among patients at a comprehensive cancer center. American Journal on Addictions, 2022, , .	1.3	0